Vygenerované: 30.01.2026 17:27:05
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry Double trouble: Tobacco use and Long COVID COVID-19 brought about lasting changes that are still being felt today in the post-pandemic era, with one being the unprecedented side effect known as Long COVID A research group led by graduate student Erika Toyokura, Dr Long COVID is characterized by symptoms affecting multiple organs and persisting for at least three months or longer after a COVID-19 infection.
Doplnenie: However, there has not been a clear conclusion in its relation to smoking.
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry Novel combined PET imaging approach personalizes treatment for head and neck cancer, reveals research A new strategy that combines two types of PET scans can guide personalized radiotherapy for head and neck cancers, according to new research published in The Journal of Nuclear Medicine Moving beyond the "one-size-fits-all approach," this research shows that treatment can be biologically tailor27 in a clinically feasible way with the potential to improve patient outcomes Conventional radiotherapy prescribes the same dose for nearly all patients based on the type of their tumor and standard tissue anatomy.
Doplnenie: Advances in PET imaging, however, allow physicians to create biologic maps that show the unique characteristics of a tumor and can be utilized to develop a personalized treatment plan.
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry FDA Approves First Dual-Agent Eye Drop for Presbyopia The FDA approved carbachol/brimonidine tartrate ophthalmic solution (Yuvezzi) for adults with presbyopia, marking the first dual-agent eye drop therapy for age-related near-vision decline Unlike previously approved presbyopia drops that contain a single active ingredient (such as pilocarpine or aceclidine), Yuvezzi combines two agents with distinct mechanisms of action, offering a novel treatment approach The Phase 3 BRIO I study demonstrated a superior benefit of the combination therapy over the individual actives – a requirement for FDA approval of a fixed-dose combination.
Doplnenie: The Phase 3 BRIO I study demonstrated a superior benefit of the combination therapy over the individual actives – a requirement for FDA approval of a fixed-dose combination.
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry Combined oral contraceptive use among people with migraine with aura persists, despite cautions: Study A new study found that a sizable minority of people with migraine with aura still receive prescriptions for estrogen-containing birth control pills and hormone therapy, despite treatment contraindications or cautions related to stroke risk Current medical guidelines discourage the use of combined oral contraceptives (COCs) among people who experience migraine with aura—a type of migraine accompanied by temporary neurological symptoms—due to a heightened risk for stroke Despite these concerns, a notable percentage of people diagnosed with migraine with aura are still receiving prescriptions for these oral contraceptives, according to a new study led by Boston University School of Public Health (BUSPH) researchers.
Doplnenie: Published in the journal Pharmacoepidemiology and Drug Safety, the study found that COC use among this population has declined over the last two decades, but not fully stopped.